# Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT00316849** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 56 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma

## Interventions

- **OTHER:** pharmacological study
- **PROCEDURE:** adjuvant therapy
- **RADIATION:** 3-dimensional conformal radiation therapy
- **RADIATION:** intensity-modulated radiation therapy
- **DRUG:** temsirolimus
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00316849
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2010-11
- **Final completion:** —
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2013-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316849, "Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00316849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*